肿瘤患者头孢哌酮和美罗培南药物抗体阳性率及影响因素分析
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R979.1

基金项目:


Drug antibody positive rates of cefoperazone and meropenem and influencing factors in tumor patients
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨头孢哌酮和美罗培南在肿瘤患者中药物抗体产生情况及与患者疾病、性别、年龄等因素的关系,为抗生素合理用药和精准医疗提供依据。方法:采用微柱凝胶法检测501例肿瘤患者使用头孢哌酮和美罗培南后药物抗体的产生情况,并分析其影响因素。结果:肿瘤患者头孢哌酮药物抗体阳性率为30.54%(124/406),美罗培南药物抗体阳性率为40.00% (38/95);头孢哌酮和美罗培南药物抗体阳性患者以血液系统肿瘤为主,阳性率分别为36.43%和40.96%;不同年龄分组的检测结果表明,31~40 岁组的头孢哌酮药物抗体阳性率最高,达到 70.37%,41~50 岁组美罗培南药物抗体阳性率最高,达到 86.67%。结论:肿瘤患者使用头孢哌酮及美罗培南后可诱导机体产生药物抗体,药物抗体的产生与疾病、性别、年龄等因素相关。

    Abstract:

    Objective:To investigate the production of drug antibodies in tumor patients treated with cefoperazone and meropenem, and to provide the basis for rational use of antibiotics and accurate medical treatment. Methods:Microcolumn gel method was used to detect the production of antibodies in 501 cases of tumor patients after using cefoperazone and meropenem,and influencing factors were analyzed. Results:The positive rate of cefoperazone drug antibody in tumor patients was 30.54%(124/406),and the positive rate of meropenem drug antibody was 40.00%(38/95). The cefoperazone and meropenem drug antibody were mainly detected in patients with blood system diseases,of which the positive rates was 36.43% and 40.96% respectively. The results of different age groups showed that the positive rate of cefoperazone drug antibody was the highest in 31~40 years old group,reaching 70.37%. The positive rate of meropenem drug antibody was the highest in 41~50 years old group,reaching 86.67% . Conclusion:The use of cefoperazone and meropenem in tumor patients could induce drug antibodies and the production of drug antibodies is related to disease,gender,and age.

    参考文献
    相似文献
    引证文献
引用本文

邵树军,祁欣,桂佳林,高明,陈玉平,王兰菊.肿瘤患者头孢哌酮和美罗培南药物抗体阳性率及影响因素分析[J].南京医科大学学报,2022,(7):978~982

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2022-07-15
  • 出版日期: